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Abstract
Background: Lipocalin 2 is a bacteriostatic protein that binds the siderophore enterobactin, an iron-chelating 
molecule produced by Escherichia coli (E. coli) that is required for bacterial growth. Infection of the lungs by E. coli is rare 
despite a frequent exposure to this commensal bacterium. Lipocalin 2 is an effector molecule of the innate immune 
system and could therefore play a role in hindering growth of E. coli in the lungs.
Methods: Lipocalin 2 knock-out and wild type mice were infected with two strains of E. coli. The lungs were removed 
48 hours post-infection and examined for lipocalin 2 and MMP9 (a myeloid marker protein) by immunohistochemical 
staining and western blotting. Bacterial numbers were assessed in the lungs of the mice at 2 and 5 days after infection 
and mortality of the mice was monitored over a five-day period. The effect of administering ferrichrome (an iron source 
that cannot be bound by lipocalin 2) along with E.coli was also examined.
Results: Intratracheal installation of E. coli in mice resulted in strong induction of lipocalin 2 expression in bronchial 
epithelium and alveolar type II pneumocytes. Migration of myeloid cells to the site of infection also contributed to an 
increased lipocalin 2 level in the lungs. Significant higher bacterial numbers were observed in the lungs of lipocalin 2 
knock-out mice on days 2 and 5 after infection with E. coli (p < 0.05). In addition, a higher number of E. coli was found in 
the spleen of surviving lipocalin 2 knock-out mice on day 5 post-infection than in the corresponding wild-type mice (p 
< 0.05). The protective effect against E. coli infection in wild type mice could be counteracted by the siderophore 
ferrichrome, indicating that the protective effect of lipocalin 2 depends on its ability to sequester iron.
Conclusions: Lipocalin 2 is important for protection of airways against infection by E. coli.
Background
Despite frequent exposure of the body to commensal bac-
teria from the intestinal system, such as E.coli, extraintes-
tinal infections are quite rare. The lungs are continuously
exposed to bacteria including E.coli and must therefore
be able to prevent bacterial growth. The innate immune
system has evolved in higher eukaryotes as the first line of
defence against potential microbial pathogens. The cells
of the epithelial lining are important players in this sce-
nario as they produce many antimicrobial proteins in
response to the invading microorganisms. Microorgan-
isms are recognized by pathogen-associated molecular
patterns (PAMPs) that specifically expressed on bacteria
and fungi [1]. These PAMPs are recognized by pathogen
recognizing receptors (PRRs) on epithelial cells and/or
interstitial macrophages and dendritic cells [1]. In the for-
mer case, an intracellular signal is generated that leads to
a direct response by the epithelial cells. In the latter case,
ligation of PAMPs to receptors on leukocytes stimulates
synthesis of pro-inflammatory cytokines that in turn will
i n d u c e  a  r e s p o n s e  i n  e p i t h e l i a l  c e l l s  [ 1 , 2 ] .  I n  b o t h
instances this will lead to de novo synthesis and secretion
of antimicrobial proteins to the immediate surroundings
of the epithelium where these proteins will exert their
biological functions. Specialized mobile phagocytes, such
as neutrophils and monocytes, will appear at the site of
infection to combat the pathogens, not least by exocytos-
ing microbicidal proteins from their stores in intracellular
granules. Antimicrobial proteins similar to those stored
in phagocytes are induced in epithelial cells by contact
with microorganisms or by cytokines. [3].
One such antimicrobial protein is lipocalin 2. Lipocalin
2 is a 25 kDa glycoprotein first identified as a matrix pro-
tein of specific granules of human neutrophils [4] and
therefore originally named neutrophil gelatinase-associ-
ated lipocalin (NGAL) [4]. It was later found that lipoc-
alin 2 is also strongly upregulated in epithelial cells
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during inflammation [2,5-8]. Lipocalin 2 belongs to the
lipocalin superfamily whose members share a barrel-
shaped tertiary structure with a hydrophobic pocket that
can bind lipophilic molecules [9]. The ligand of lipocalin
2 is bacterial ferric siderophores. Siderophores are gener-
a t e d  b y  m i c r o o r g a n i s m s  w h e n  l a c k  o f  s o l u b l e  i r o n
becomes a limiting factor for their growth. Siderophores
are the strongest iron chelators known and are used by
b a c t e r i a  f o r  u p t a k e  o f  i r o n  [ 1 0 , 1 1 ] .  B i n d i n g  o f  s i d e r o -
phores by lipocalin 2 deprives bacteria of iron and lipoc-
alin 2 consequently acts as a bacteriostatic protein.
It has been demonstrated previously that lipocalin 2 is
protective against infection by E. coli injected directly
into the peritoneum [11]. That model, however, circum-
vents the important barrier against microbial infections
provided by the epithelial lining of our mucous mem-
branes. We therefore decided to investigate whether
lipocalin 2 has a role in protection against E. coli when
these are introduced in the airways and need to overcome
the protection provided by the epithelial lining in order to
establish infection. We demonstrate that intratracheal
installation of E. coli induces strong expression of lipoc-
alin 2 in the epithelial cells of the respiratory tract and
that lack of lipocalin 2 expression results in increased
morbidity and mortality of the infected mice. These data
support the idea that the innate immune system is impor-
tant for hindering infection by commensal bacteria such
as E. coli.
Methods
Bacterial strains and culture conditions
The E. coli strains HB101 (ATCC 33694) and H9049 (a
clinical isolate kindly provided by Dr. Alan Aderem, Insti-
tute for Systems Biology, Seattle, WA) were selected for
the experiments, as they depend on enterobactin for
uptake of iron. The bacteria were grown in Luria-Broth
medium overnight with agitation at 37°C before being
used for the experiments. The bacteria were harvested,
resuspended in PBS, and the suspension of bacteria
adjusted to the concentration required for the experi-
ment. The titer of the bacteria was controlled by serial
dilutions and cultures of the inoculum.
Mouse model for lung infection
Eleven-week-old female lipocalin 2 (Lcn2) knock-out and
wild-type littermates, both in a C57BL/6 background,
were used for the experiments. The knock-out mice were
kindly provided by Dr. Shizuo Akira, Osaka University,
Osaka, Japan and Dr. Alan Aderem, Institute for Systems
Biology, Seattle, WA. The Lcn2 knock-out mice used in
the experiments had been back-crossed to C57BL/6 mice
for 8 or 9 generations. A detailed protocol for bacterial
inoculation has been described previously [12]. In brief,
before surgical procedure, all mice were anesthetized by
subcutaneous injection of a 1:1 mixture of etomidat
(Janssen, Birkerød, Denmark) and midazolam (Roche,
Hvidovre, Denmark) at a dose of 10 μl/g body weight.
Tracheotomy was then performed and 40 μl bacterial sus-
pension was instilled into the tracheal via a curved bead-
tipped needle. The mice were infected with 4-8 × 107 E.
coli/mouse. The incision was sutured with silk and healed
without complications. The animals were sacrificed by
20% pentobarbital (DAK, Copenhagen, Denmark) at 2 μl/
g body weight. Desferri-ferrichrome (without iron) and
iron-loaded ferrichrome (both from EMC microcollec-
tions, Tübingen, Germany) were resuspended in sterile
water and added to the bacterial suspension prior to
infection of the mice. All animal experiments were con-
ducted in accordance with the guidelines of the Danish
Animal Ethics Committee.
Lung and spleen bacteriologies
Quantification of bacteria in organs from challenged
mice was performed as described previously [13]. In
short, lungs or spleens were removed aseptically from the
mice and immediately put into sterile containers with 5
ml of 4°C sterile PBS. Lung and spleen samples were
homogenized with a blender (Heidolph, Struers, Den-
mark) at 4°C and series of diluted samples were plated on
agar plates and incubated at 37°C for quantitative bacteri-
ological examination after 20-24 hours of incubation. The
resulting bacterial load is expressed as colony formation
units (CFU)/lung or CFU/spleen.
Immunhistochemical staining
Whole lungs and femur were removed from the mice and
fixed overnight at 4°C in 10% buffered formalin. The bone
tissue was decalcified by 4 mol/l formic acid and 0,5 mol/
l natriumformate. Lung and bone tissues were then
embedded in paraffin, and 4 μm-thick sections obtained
by microtome were mounted onto coated glass slides and
afterward deparaffinized and rehydrated according to
standard protocols. Subsequently, the antigens of interest
were retrieved in a microwave-oven in Tris/EGTA (TEG)
buffer pH 9.0 for 18 min, at 600 watt. Then, the sections
were let to cool-down in TEG buffer for 20 min, rinsed,
and incubated in 3% H2O2 in methanol for 15 min to
block endogenous peroxidase activity. For immunohis-
tochemical detection of lipocalin 2, we used a rabbit poly-
clonal antibody (dilution 1:250) generated in our
laboratory according to a protocol previously described
[14]. Metalloproteinase-9 (MMP9) was detected using
rabbit polyclonal anti-MMP9 antibody (Ab38898,
Abcam, Biosite; dilution 1:2000) The antibodies were
incubated in TBS with 1% BSA for 30 min. T o rule out
non-specific binding, rabbit serum collected before
immunization with lipocalin 2 (pre-immune serum) and
a nonspecific rabbit Ig (DAKO, no. X0903, Dako,Wu et al. Respiratory Research 2010, 11:96
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Glostrup, Denmark) were used as negative controls for
lipocalin 2 and MMP-9 antibodies, respectively, in the
same dilutions as for the specific antibodies. DAKO Envi-
sion-System-horseradish peroxidase (HRP) (DakoCyto-
mation, no. K4011) with diaminobenzidine as substrate
chromogen was used according to manufacturer's
instructions to visualize the binding of the primary anti-
bodies. The samples were counterstained with Mayer's
hematoxylin for 1 min.
SDS-PAGE and immunoblotting
For immune-detection, the proteins from lung lysates
were separated on a 4-12% NuPAGE Bis-Tris gel (Invitro-
gen) and electro-transferred to a Trans-Blot nitrocellu-
lose membrane (Bio-Rad) according to the
manufacturer's instructions. The membrane was blocked
for 1 h with 5% skimmed milk and washed four times 5
min. in PBS with 0.5% BSA. The primary antibodies for
lipocalin 2 (AF1857, R&D systems, dilution 1:1000),
MMP9 (Ab38898, Abcam, dilution 1:1000), and β-Actin
(13E5, Cell Signaling, dilution 1:5000)) were incubated
overnight at 4°C in PBS with 0.5% BSA and then washed
four times 5 min. in PBS with 0.5% BSA. The membranes
were next incubated for 2 hours with the secondary anti-
body (peroxidase-conjugated goat anti-rabbit antibodies
(P0448, DAKO, dilution 1:1000)), washed four times 5
min. in PBS with 0.5% BSA and visualized by chemilumi-
nescence (SuperSignal West Pico, Thermo Scientific).
Statistics
The unpaired differences in the continuous data between
infected and non-infected mice were analyzed by the
Mann-Whitney U-test. The software Statview (SAS Insti-
tute, Cary, NC) was used for the statistical analysis. Sta-
tistical significance was reported if p < 0.05 was achieved.
Results
Infection of the respiratory tract induces lipocalin 2 
expression in bronchial epithelium and type II 
pneumocytes
We have previously demonstrated a strong up-regulation
of lipocalin 2 in human bronchial epithelium in connec-
tion with bacterial infections [8]. To investigate whether
this is the case also in a mouse model, we analysed lung
sections of C57BL/6 mice that had been challenged by
bacterial infection. As demonstrated by immunohis-
tochemistry shown in fig. 1, a strong up-regulation of
lipocalin 2 was observed at 48 hours post-infection in
response to bacterial challenge with E. coli H9049. This
was observed both in the bronchial epithelium (fig. 1B)
and in type II pneumocytes of the alveoli as identified by
their typical morphology (fig. 1F). In contrast, almost no
staining for lipocalin 2 was observed in the bronchial epi-
thelium (fig. 1A) or alveoli (fig. 1E) of uninfected wild-
type mice. Besides the induced synthesis of lipocalin 2 in
epithelial cells, lipocalin 2 is also expressed during neu-
trophil development in the bone marrow and stored in
exocytosable granules [4]. Accordingly, positive staining
for lipocalin 2 was seen in bone marrow neutrophils of
Figure 1 Lipocalin 2 expression in the lungs of E. coli-infected 
mice. Immunohistochemical staining using a polyclonal antibody 
against lipocalin 2 (diluted 1:250) on formalin-fixed lung sections re-
moved 48 hours post-infection with E. coli H9049. Weak staining for li-
pocalin 2 is found in uninfected bronchial epithelium (A) and alveolear 
tissue (E) of wild-type C57BL/6 mice. Strong induction is seen following 
E. coli infection (4 × 107 CFU E. coli H9049/mouse) in wild-type mice (B 
and F) whereas no staining for lipocalin 2 is seen in infected Lcn2 
knock-out mice (C and G). The specificity of the reaction is demonstrat-
ed by the lack of staining when using rabbit pre-immune serum (dilu-
tion 1:250) as negative control (D and H). Staining for lipocalin 2 was 
also observed in neutrophils in the bone marrow of wild-type mice (I) 
but not in Lcn2 knock-out mice (J) or in wild-type mice incubated with 
pre-immune serum (K).Wu et al. Respiratory Research 2010, 11:96
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wild-type mice (Fig. 1I). To examine the effect of lipocalin
2 in the defence against pulmonary bacterial infections,
we employed a previously described lipocalin 2 knock-
out mouse [11]. As expected, no staining for lipocalin 2
was observed in bronchial epithelium or lung alveoli of
knock-out mice infected by bacteria, nor in bone marrow
neutrophils (Fig. 1C, G, and 1J).
The amount of lipocalin 2 in lung lysates increases 
dramatically following infection
In order to evaluate the level of lipocalin 2-induction fol-
lowing bacterial challenge of the lungs, we isolated pro-
tein from whole cell lysates of uninfected and infected
lungs from both wild-type and lipocalin 2 knock-out
mice. As seen in the immunoblot in figure 2, stronger
expression of lipocalin 2 was observed in the infected
wild-type mouse compared to the uninfected wild-type
mouse. As expected, no expression of lipocalin 2 was
observed in the knock-out mice, regardless of whether
they were infected or not. Staining for the metalloprotei-
nase 9 (MMP9), which is constitutively present in neutro-
phil granules, was performed to evaluate the influx of
neutrophils into the tissues. An increase in staining was
found for both infected wild-type and knock-out mice
using MMP9 and cellular morphology as markers, indi-
cating that migration of neutrophils to the infected lung
was not abolished in the lipocalin 2 knock-out mouse (fig.
2B and 2E).
Lipocalin 2 protects against lung infection by E. coli
We chose to test the susceptibility of the mice against two
strains of E. coli that are dependent on enterobactin for
iron uptake, namely HB101 [15] and H9049 [11]. We first
examined the effect of a short-term infection (48 hours)
of a lipocalin 2 knock-out mouse compared to wild-type
littermates. At this time-point, no mice had succumbed
to the infection, but a significant higher number of bacte-
ria was found in the lungs of the knock-out mice (HB101,
p = 0.048 and H9049, p = 0.0033) as seen in figure 3A and
3B. We also examined the spleen of these animals to
determine whether the bacteria had been able to cross
the epithelial lining of the lung and infect internal organs.
No bacteria were found in the spleen of either type of
mice inoculated with E. coli HB101 whereas infection of
the spleen with a significant higher number of bacteria
was observed in knock-out mice compared to the wild-
type when these were challenged with E. coli H9049 (p =
0.019) (fig. 3C). These data clearly demonstrate that
lipocalin 2 has a protective effect against this E. coli
strains.
We investigated the effect of the E. coli infection after a
longer incubation period. For this experiment, we
decided to use E. coli H9049, as it appeared to be more
virulent than HB101. After five days, almost half the
knock-out mice (44%) had died in comparison to only one
(8%) of the wild-type mice and the study was finalized
(fig. 4A). We found a significantly higher bacterial load in
the lungs of the surviving lipocalin 2 knock-out mice
compared to the number of bacteria in the wild-type
mice (p = 0.028) (fig. 4B). A higher bacterial load was also
found in the spleen of knock-out mice compared to the
wild-type (p = 0.024) (fig. 4C).
Figure 2 MMP9 expression in the lungs of E. coli-infected mice. 
Top. Western blot analysis for lipocalin 2 (Lcn2) and MMP9 (both anti-
bodies diluted 1:1000) of whole lung lysates from uninfected and E. 
coli-infected (4 × 107 CFU E. coli H9049) wild-type (+/+) and Lcn2 
knock-out (-/-) mice. Immunostaining for β-actin (dilution 1:5000) was 
included to assure equal loading of the samples. Bottom. Immunohis-
tochemical staining for the neutrophil granule protein MMP9 (dilution 
1:2000) on formalin-fixed lung sections of wild-type (A-C) and Lcn2 
knock-out (D-F) mice. Only a few positive cells were found in the lungs 
of uninfected mice (A and D) whereas a larger number of cells were 
stained in the lungs of E. coli infected mice (4 × 107 CFU E. coli H9049/
mouse) (B and E). No staining was seen when using a non-specific rab-
bit Ig as negative control (C and F).Wu et al. Respiratory Research 2010, 11:96
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The bacteriostatic effect of lipocalin 2 is dependent on its 
ability to bind siderophores
It is known that lipocalin 2 is unable to bind all types of
siderophores produced by microorganisms [16]. One
example is ferrichrome, which is a siderophore of the
hydroxymate type produced by fungi. Although E. coli
does not produce ferrichrome it carries receptors for fer-
richrome and is thus able to take up iron via this sidero-
phore [17]. To demonstrate that the effect of lipocalin 2 is
due to iron-depletion through binding of enterobactin,
we infected wild-type C57BL/6 mice with E. coli H9049
with and without ferrichrome added to the bacterial inn-
oculum. A significantly higher number of bacteria (p =
0.03) were observed five days after infection in the lungs
of the mice that had received E. coli H9049 along with
desferri-ferrichrome compared to the mice that only were
exposed to the bacteria (fig. 5). This effect was even more
pronounced if ferrichrome, pre-loaded with iron, was co-
inoculated with the E. coli strain as 3 of the 13 mice died
at days 2, 3, and 4, respectively. Furthermore, the bacte-
rial load in the lungs of the surviving 10 mice was higher
than in the mice only receiving E. coli H9049 (p = 0.01). A
group of mice receiving ferrichrome, but no bacteria, was
also included in the study. As expected, no bacteria were
found in the lung lysates of these mice (data not shown).
Figure 5 The bacterial load increases in the lungs of mice admin-
istered ferrichrome. Bacterial numbers (CFU) after 5 days in the lungs 
of wild-type mice infected with 4 × 107 CFU E. coli H9049/mouse alone 
(n = 9) or with 25 mmol desferri-ferrichrome (Des) (n = 10) or iron-load-
ed ferrichrome (Fer) (n = 13). Three of the mice infected with E. coli 
H9049 and iron-loaded ferrichrome died and bacterial loads were de-
termined only for the 10 mice surviving to day 5. The number of bac-
teria in lungs of mice inoculated only with bacteria was significantly 
lower that in mice also receiving desferri-ferrichrome (p < 0.05) or iron-
loaded ferrichrome (p < 0.01). The amount of CFU/lung of mice receiv-
ing desferri-ferrichrome + E. coli H9049 was significantly lower than the 
amount measured in the lungs of the surviving mice that had been ad-
ministered E. coli H9049 + iron-loaded ferrichrome (p < 0.05). No bac-
teria were measured in the mice receiving only iron-loaded 
ferrichrome (n = 6).
Figure 3 Bacterial numbers in the lungs at 48 hours post-infec-
tion. Data are presented as box plots showing CFU/lung (log 10 scale) 
in wild-type (wt) and Lcn2 knock-out (ko) mice infected with E. coli 
HB101 or H9049 (both 8 × 107 CFU/mouse) and tested after 48 hours. 
(A) For E. coli HB101, a statistical significant difference between the CFU 
in the lungs of wild-type (n = 9) and Lcn2 knock-out mice (n = 8) was 
observed (p < 0.05). No bacteria were measured in the spleen of these 
mice. For E. coli H9049, a significant difference was observed for CFU 
from the lungs (B) (p < 0.01) and spleen (C) (p < 0.05) of wild-type (n = 
8) and Lcn2 knock-out (n = 8) mice.
Figure 4 Lcn2 knock-out mice are highly susceptible to lung in-
fection with E. coli H9049. (A) Survival curves of wild-type (wt) (n = 
12) and lipocalin 2 knock-out (ko) (n = 16) mice infected with 4 × 107 
CFU E. coli H9049/mouse demonstrating a significant higher mortality 
(p < 0.05) of the knock-out mice. Box plots showing bacterial numbers 
(CFUs) for the surviving mice (ko (n = 9) and wt (n = 11)) in the lungs 
(B) and spleens (C). A significantly higher number of bacteria were 
found in both the lungs (p < 0.05) and spleens (p < 0.05) of Lcn2 knock-
out mice than in wild-type mice.Wu et al. Respiratory Research 2010, 11:96
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Discussion
The human orthologue of lipocalin 2, NGAL, is constitu-
tively expressed in the goblet cells of trachea and is
strongly upregulated in the epithelial lining of the upper
airways and in type II pneumocytes of the alveoli follow-
ing lung infection [8]. Expression of lipocalin 2 is induced
in epithelial cells in an NF-κB dependent manner follow-
ing stimulation with pro-inflammatory cytokines and
constitutively secreted to the surroundings [2,8]. Further-
more, lipocalin 2 is stored in the specific granules of neu-
trophils from which it may be exocytosed when these
cells have migrated to a site of infection [3,4].
Mice that do not express lipocalin 2 have previously
b e e n  d e m o n s t r a t e d  t o  b e  m o r e  s u s c e p t i b i l i t y  t o w a r d s
intraperitoneal  E. coli i n f e c t i o n s  t h a n  w i l d  t y p e  m i c e
[11,18]. We show here that lipocalin 2 also plays a role in
protection against E. coli when the bacteria are encoun-
tered on the epithelial surface of the lower airways. In the
present study, the wild-type mice had a significantly
lower pulmonary and spleen bacterial load in a pneumo-
nia model with E. coli HB101 and H9049 at 48 hours
compared to the Lcn2 knock-out mice. Furthermore, in
the late pneumonic phase (5 days after intratracheal chal-
lenge with E. coli H9049), significant higher survival rates
as well as a lower bacterial load in the lungs and spleens
were found in wild-type mice compared to Lcn2 knock-
out mice. These results indicate that lipocalin 2 has an
important protective effect against lung infections caused
by bacteria that produce siderophores, which are ligands
for lipocalin 2. This is in accordance with the findings
from other researchers [11,18].
Strong immunostaining for lipocalin 2 is seen in bron-
chial epithelial cells and in type II pneumocytes of the
alveoli following infection with E. coli. A comparable
increase in the amount of the neutrophil granule protein
MMP9 was observed in the lung lysates of wild-type and
Lcn2 knock-out mice by immunoblotting. This indicates
that recruitment of myeloid cells to the infected lung was
not impaired in the knock-out mice. This is supported by
immunohistochemical staining of lung tissue from wild-
type and Lcn2 knock-out mice where comparable levels
of MMP9 positive cells are seen which were identified as
neutrophils by morphology. Furthermore, the increase in
lipocalin 2 expression between uninfected and E. coli-
infected wild-type mice appeared to be more pronounced
than the increase in MMP9 expression, which indicates
that a considerable amount of the lipocalin 2 measured in
these samples was secreted by the epithelial cells. A
recent report describes induction of lipocalin 2 in lung
cells following infection with Klebsiella pneumonia and
points to a toll-like receptor 4 (TLR4)-mediated induc-
tion pathway [19]. Whether this mechanism also is
involved in E. coli-induced lipocalin 2 expression is not
known but as TLR4 is expressed both on epithelial cells
and monocytes-derived dendritic cells of the airways
[20], it is a plausible mechanism.
The data presented here suggest that the lipocalin 2
released locally in the lungs either by import of myeloid
cells or generated by the epithelial cells is an important
factor in preventing dissemination of an E. coli infection
in mice and suggests that this may also be the case in
humans. The bacteriostatic effect exerted by lipocalin 2 is
caused by its ability to bind iron-loaded siderophores and
thus sequester the iron needed for bacterial growth. Add-
ing a siderophore that can be taken up by the bacteria but
is unable to be bound by lipocalin 2 should therefore be
able to counteract this effect. Ferrichrome fulfils these
requirements as demonstrated in the intraperitoneal
infection model [11]. This is also the case in the lung
infection model presented here where a higher bacterial
load was measured in the lungs of mice infected with a
bacterial suspension containing ferrichrome than in the
lungs of mice administered the same amount of bacteria
without ferrichrome. The observation that an even higher
bacterial load was observed in mouse lungs where iron-
loaded ferrichrome was added to the bacteria rather than
desferri-ferrichome further supports this notion.
Infection of the lungs with Enterobacteriaceae is much
more common with K. pneumonia than with E. coli. A
recent report demonstrated no difference between the
degree of colonisation of K. Pneumonia in wild-type and
lipocalin 2 knock-out mice [21]. This was due to the abil-
ity of this bacterium to form both a modified (glycosy-
lated) form of enterobactin and a second siderophore,
yersiniabactin (Ybt), of which neither can be bound by
lipocalin 2. When testing a mutated form of K. Pneumo-
nia that was unable to synthesize Ybt as well as glycosy-
late enterobactin, wildtype mice were able to combat
infection with this bacterium whereas lipocalin 2 defi-
cient mice were not [21]. This argues that it is the ability
of this bacterium to use a modified enterobactin as well
as a second type of siderophore as iron scavenger that
make K. Pneumonia a pathogen of the lungs. The E. coli
strain H9049 used in this study is also able to evade the
bacteriostatic effect of lipocalin 2 if it acquires the iroA
cluster that encodes the proteins involved in modification
of enterobactin to the glycosylated form [22]. This was
demonstrated in an intraperitoneal infection model
where injection of E. coli H9049 carrying the iroA cluster
caused a marked increase in the mortality of wild-type
mice compared to mice receiving the unmodified form of
H9049 [22]. It is thus possible for bacteria to evade the
protective effect of lipocalin 2 either by biochemical
modification of enterobactin or by acquiring iron by
another method than chelation by enterobactin. This is
likely to be a trait of many lung pathogens as exemplified
by Streptococcus pneumoniae and Haemophilus influen-
zae. Both of these bacterial strains readily infect mice inWu et al. Respiratory Research 2010, 11:96
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an intranasal inoculation model despite a strong up-regu-
lation of lipocalin 2 in the nasal epithelium in response to
the infection [23]. The reason why these lung pathogens
can evade the bacteriostatic effect of lipocalin 2 is that
neither of these two bacterial strains produces sidero-
phores nor use them for iron acquisition but instead have
developed other means of iron uptake [23].
Infections of the respiratory system by E. coli do, how-
ever, occur, and may have severe implications in humans.
E. coli lung infections or pneumonia are observed in
patients with haematological diseases [24] and in patients
that need mechanical ventilation in hospital ICU units
[25]. Recently, a report was published describing a signifi-
cantly higher number of E. coli or Staphylococcus aureus
in microbiological samples from cases of sudden unex-
pected death in infancy (SUDI) than in infants whose
death was due to a non-infectious cause [26]. It was sug-
gested that the presence of E. coli could be associated
with SUDI although a direct link was not demonstrated.
It is known that the level of lipocalin 2 expression varies
considerably between different individuals [27] and it
may thus be possible that this could play a role in the sus-
ceptibility to E. coli infections. Our data demonstrate that
the innate immune system plays a significant role in keep-
ing infections by bacteria, which are normally considered
to be non-pathogenic, at bay. If the innate immune sys-
tem, on the other hand, is compromised then there is a
risk that otherwise harmless commensal bacteria may
cause infection of our body.
Conclusion
Our data demonstrate that lipocalin 2 is important for
hindering infection of the lungs by E. coli. E. coli is usually
considered a non-pathogenic bacterium unless it has
attained a specific trait that enables it to overcome the
natural defence mechanisms of the body. Our data dem-
o n s t r a t e  t h a t  i f  t h e  i n n a t e  i m m u n e  s y s t e m  i s  c o m p r o -
mised - in t his case by inactiva ting t he gene encoding
lipocalin 2 - then also normally non-pathogenic E. coli
can become infectious. This underscores the importance
of the innate immune system in the defence of the body
against microorganisms
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